Sarpogrelate

MedChemExpress

Cat. No.:	HY-10563	
CAS No.:	125926-17-2	
Molecular Formula:	$C_{24}H_{31}NO_6$	
Molecular Weight:	429.51	
Target:	5-HT Receptor	
Pathway:	GPCR/G Protein; Neuronal Signaling	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY			
BIOEOGICAE ACTIVITY			
Description	Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT ₂ receptor antagonist, Sarpogrelate increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger's disease ^[1] .		
IC ₅₀ & Target	5-HT ₂ Receptor		
In Vitro	Sarpogrelate (MCI-9042) induces a significant decrease in plasma serotonin (5-HT) concentration and after 2 weeks increases significantly the concentration of whole blood 5-HT ^[1] . Sarpogrelate increases significantly plasma tryptophan concentration after 2 and 4 weeks, and no changes in plasma 5-HIAA concentration ^[1] . Sarpogrelate also has a tendency to increase the concentration of whole blood tryptophan concentration, did not show significant changes in platelet aggregation induced by ADP and collagen ^[1] . Sarpogrelate increases significantly platelet aggregation induced by serotonin after 2 weeks ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

CUSTOMER VALIDATION

• Exp Neurol. 2019 Nov;321:113030.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. A Rydzewski, et al. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res. 1996 Dec 15;84(6):445-52.

Inhibitors

•

•

Proteins

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA